Nymox Pharmaceutical
NYMX
#8019
Rank
$18.25 M
Marketcap
Bahamas
Country
$0.20
Share price
0.00%
Change (1 day)
-47.37%
Change (1 year)

P/E ratio for Nymox Pharmaceutical (NYMX)

P/E ratio as of March 2024 (TTM): -3.33

According to Nymox Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.33333. At the end of 2022 the company had a P/E ratio of -4.00.

P/E ratio history for Nymox Pharmaceutical from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-4.00-53.85%
2021-8.67-40.59%
2020-14.632.62%
2019-11.059.54%
2018-6.89-45.68%
2017-12.733.1%
2016-9.5436.64%
2015-6.98109.36%
2014-3.33-92.86%
2013-46.756.55%
2012-29.812.48%
2011-26.5-24.67%
2010-35.223.51%
2009-28.534.01%
2008-21.3-33.58%
2007-32.069.68%
2006-18.925.91%
2005-15.0-14.6%
2004-17.6-0.97%
2003-17.7-17.72%
2002-21.5-22.7%
2001-27.9

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
11.2-436.93%๐Ÿ‡บ๐Ÿ‡ธ USA
14.9-547.58%๐Ÿ‡บ๐Ÿ‡ธ USA
38.2-1,247.23%๐Ÿ‡บ๐Ÿ‡ธ USA
143-4,398.67%๐Ÿ‡บ๐Ÿ‡ธ USA
19.7-690.72%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.